Semaglutide (oral)
The same peptide as injectable semaglutide, formulated with an absorption enhancer so it survives the stomach. Approved for type 2 diabetes, with a completed cardiovascular outcomes trial.
Metabolic & Weight
Orforglipron
A small-molecule GLP-1 agonist taken as a tablet with no food or water restrictions. Phase 3 results in obesity and type 2 diabetes have been reported.
Overview
Every GLP-1 drug before this was a peptide, which meant either an injection or a tablet that had to be taken on an empty stomach with strict timing to survive digestion. Orforglipron is not a peptide at all — it is a conventional small molecule that happens to fit the GLP-1 receptor. That means it can be swallowed like any other tablet, without the absorption enhancer or the fasting window that oral semaglutide requires.
A non-peptidic, biased partial agonist at GLP-1R that engages an extracellular allosteric pocket distinct from the orthosteric peptide-binding site. Signalling is biased toward Gs/cAMP over beta-arrestin recruitment, which is proposed to limit receptor internalisation. Oral bioavailability is independent of food and does not require SNAC or similar permeation enhancers. Phase 3 ATTAIN and ACHIEVE programmes reported weight reduction and HbA1c lowering in obesity and type 2 diabetes respectively.
Research areas
ObesityType 2 diabetesOral incretin therapy
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Titrated once-daily oral dosing to a 12, 24 or 36 mg maintenance dose over 72 weeks | ATTAIN phase 3 obesity programme |
| Once-daily oral dosing up to 45 mg in the phase 2 type 2 diabetes study | Frias et al., New England Journal of Medicine 2023 |
Trial status
Phase 3 ATTAIN (obesity) and ACHIEVE (type 2 diabetes) programmes completed and reported.
Reported safety signals
- Gastrointestinal adverse effects — nausea, vomiting, diarrhoea, constipation — are the dominant issue, as with injectable GLP-1 agonists.
- Long-term safety beyond the trial durations is not yet established.
- Class warnings for GLP-1 receptor agonists, including the rodent thyroid C-cell signal, apply pending full labelling.
Common questions
Is orforglipron a peptide?
No. It is a small molecule that binds the same receptor. That is precisely why it can be formulated as an ordinary tablet — there is no peptide backbone for stomach enzymes to destroy.
How does it compare to oral semaglutide?
Oral semaglutide is a peptide protected by an absorption enhancer, and it must be taken fasted with a small sip of water and nothing else for 30 minutes. Orforglipron has no such requirement. Weight-loss magnitude in phase 3 was broadly comparable to injectable semaglutide 2.4 mg, though no head-to-head trial has been published.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →